The research team followed 284 patients with cervical cancer who underwent radical surgery followed by adjuvant concurrent chemoradiotherapy, a standard approach for women whose tumors show high-risk features after hysterectomy. Every blood abnormality observed during treatment was graded according to the Common Terminology Criteria for Adverse Events version 5.0, the widely used scale that ranks toxicity from grade 0 to grade 4. Patients were then divided into two groups: a mild group of 163 patients whose worst toxicity never exceeded grade 2, and a severe group of 121 patients who experienced grade 3 or grade 4 toxicity at some point during their course of therapy.

The single most striking finding was the behavior of lymphocytes, the white blood cells that include the T cells and B cells responsible for adaptive immunity. Lymphopenia occurred in 100.0 percent of patients, making it the only adverse event that touched every single participant in the study. More alarmingly, 37.67 percent of patients developed grade 3 or grade 4 lymphopenia, the levels at which infection risk climbs sharply and clinical attention becomes mandatory. Lymphopenia also arrived earlier than any other blood abnormality, with a median onset time of 16.5 days from the start of treatment, and it progressed to grade 3 or 4 severity at a median of just 25 days, meaning that by roughly the third or fourth week of a typical six-week course, more than a third of patients had already lost most of their circulating lymphocyte pool.

The broader spectrum of toxicity followed a predictable hierarchy of bone marrow sensitivity. Leukopenia, the general depletion of white blood cells, affected 93.66 percent of patients, while neutropenia, the loss of the neutrophils that form the first line of antibacterial defense, occurred in 74.65 percent. Anemia, the reduction of oxygen-carrying red blood cells, developed in 60.92 percent of patients, and thrombocytopenia, the loss of the platelets responsible for clotting, appeared in 21.83 percent. This pattern reflects the biology of pelvic irradiation combined with systemic chemotherapy: the rapidly dividing progenitor cells of the lymphoid lineage are the most vulnerable to DNA damage, followed by the granulocyte lineage, with the longer-lived red cells and platelets declining more slowly and less severely.

Using multivariable logistic regression to separate true independent risk factors from statistical noise, the researchers identified three factors that remained associated with severe hematological adverse events. Patients with FIGO stage IIB to IIIC disease, meaning locally advanced tumors that had spread beyond the cervix but not to distant organs, carried roughly double the odds of severe toxicity compared with earlier stages, with an odds ratio of 2.148 and a 95 percent confidence interval of 1.271 to 3.628. A history of neoadjuvant chemotherapy given before surgery independently increased the odds by 2.438-fold, with a confidence interval of 1.156 to 5.141, plausibly because the marrow had already been stressed before chemoradiotherapy began. The most powerful predictor, however, was a dosimetric measure of radiation exposure: when the volume of pelvic bone marrow receiving at least 40 gray, known as V40, reached 41 percent or more, the odds of severe toxicity jumped 7.389-fold, with a confidence interval of 3.712 to 14.710.

The pelvic bone marrow finding carries particular technical significance for radiation oncology. The flat bones of the pelvis, including the ilium, sacrum, and pubic bones, harbor a substantial reservoir of active hematopoietic marrow, and conventional radiation fields designed to cover lymph node drainage regions inevitably pass through these bones. When more than 41 percent of the pelvic marrow volume absorbs at least 40 gray, the progenitor cells within that exposed volume are effectively knocked out, and the remaining unirradiated marrow must compensate for the entire blood supply. The sevenfold increase in severe toxicity risk at this threshold suggests that V40 could serve as a practical planning constraint, guiding physicists and physicians to spare marrow volume during intensity-modulated treatment design in the same way they already constrain doses to the kidneys, bowel, and spinal cord.

The clinical consequences of severe toxicity were substantial and measurable. Compared with the mild group, patients in the severe group experienced longer durations of hematological adverse events and significantly higher rates of chemotherapy delay, chemotherapy dose reduction, and radiotherapy interruption. These disruptions matter because the effectiveness of concurrent chemoradiotherapy depends on maintaining treatment intensity: delaying or weakening the systemic component can compromise the short-term response. Indeed, the 3-month complete response rate was lower in the severe group than in the mild group, at 70.3 percent versus 82.8 percent, a difference that reached statistical significance with a P value of 0.012. Severe lymphopenia was also associated with a higher incidence of infection during treatment and with a higher pretreatment neutrophil-to-lymphocyte ratio, an inflammatory marker that may itself reflect a marrow already skewed toward stress before therapy commenced.

The connection between severe lymphopenia and infection deserves particular emphasis in the context of cancer treatment. Lymphocytes are not merely passive casualties of therapy; they are the cells that coordinate immune defense against bacterial, viral, and fungal pathogens, and they also participate in antitumor immune surveillance. When more than a third of patients lose their lymphocyte pool to grade 3 or 4 depletion within the first month of treatment, the clinical team must weigh the risk of opportunistic infection against the need to keep the treatment schedule intact. The finding that severe lymphopenia correlated with a higher pretreatment neutrophil-to-lymphocyte ratio hints that patients with a pre-existing inflammatory or stress profile may be more vulnerable to profound depletion once chemoradiotherapy begins, offering a potential blood-based screening tool that could be calculated from routine complete blood counts before the first fraction of radiation is delivered.

The study’s retrospective design and single-center cohort of 284 patients mean that the findings require validation in larger, prospective, and multi-institutional populations before they can be translated directly into clinical guidelines. Nevertheless, the authors argue that the practical implications are clear: early risk assessment before treatment begins, deliberate optimization of pelvic bone marrow dosimetry during radiation planning, and individualized supportive management, including growth factor support and prophylactic antimicrobial strategies for high-risk patients, may together reduce the burden of severe hematological toxicity. As concurrent chemoradiotherapy remains a cornerstone of adjuvant therapy for cervical cancer worldwide, identifying which patients will tolerate the full course and which will need treatment modification is a step toward preserving both the safety and the effectiveness of one of the most important regimens in gynecologic oncology.

Subject of Research: Spectrum and influencing factors of hematological adverse events associated with postoperative adjuvant concurrent chemoradiotherapy for cervical cancer

Article Title: Spectrum and influencing factors of hematological adverse events associated with postoperative adjuvant concurrent chemoradiotherapy for cervical cancer

Article References: Zhang, Z., Wu, T., Du, Y., Tian, W., Gong, S., Li, Z., & Xiao, Z. (2026). Spectrum and influencing factors of hematological adverse events associated with postoperative adjuvant concurrent chemoradiotherapy for cervical cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-16900-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16900-8

Keywords: Spectrum, influencing, factors, hematological, adverse, events, associated, postoperative, adjuvant, concurrent, chemoradiotherapy, cervical